Page 5 - Aser Surgery News Today

Prisons should offer abundant opportunities for HIV screening and comprehensive pre-exposure prophylaxis (PrEP) adherence programs to benefit incarcerated individuals and carceral systems as a whole.

Epic’s Payer Platform is being integrated with Highmark’s claims data on Google Cloud, the companies announced Monday at ViVE. This will give providers better insight into patients' health.

Vale Health announced its launch on Monday at ViVE. The startup's platform helps health systems connect their patients to health and wellness products, which are becoming increasingly interesting to consumers. Vale has 16 founding health systems partners that will go live with the platform, with the Froedtert & the Medical College of Wisconsin health network being the first.

In an interview at the Vive conference in Los Angeles, John Couris said that while he is sympathetic toward Change Healthcare's current woes, he wants definitive answers soon.

There is a ubiquitous lack of understanding and regulation surrounding the HCSM coverage which leaves hospitals stuck with the bill and negatively impacts the bottom line.

As the role of AI in healthcare settings continues to evolve and generate debate, here are seven things to keep an eye on.

The weight loss achieved by Viking Therapeutics’ obesity drug tops results posted by Eli Lilly’s Zepbound in its pivotal test. But Viking still needs to show its results can hold up in a larger Phase 3 clinical trial.

Blackbird Health's $17 million Series A funding round was led by Define Ventures and included participation from Frist Cressey Ventures and GreyMatter. In total, the startup has raised nearly $23 million.

The way dentistry has embraced technological innovation to make patient care both safer and more comfortable serves as an example for the rest of the healthcare sector.

In preclinical testing, combining BioAge Labs’ experimental drug with Eli Lilly weight drug Zepbound led to greater weight loss compared with Zepbound alone. Now the company plans to run a Phase 2 study to see if it can replicate those results in humans.